Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

Interest Coverage N/A
WX's Interest Coverage is ranked higher than
71% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. WX: N/A )
Ranked among companies with meaningful Interest Coverage only.
WX' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: N/A
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WX's 30-Y Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

WX Guru Trades in

Q2 2015

WX Guru Trades in Q2 2015

Value Partners 209,522 sh (New)
First Eagle Investment 10,000 sh (New)
Ron Baron 341,500 sh (unchged)
Matthews Pacific Tiger Fund 2,243,158 sh (unchged)
Jim Simons Sold Out
Mario Gabelli 54,200 sh (-5.24%)
Columbia Wanger 1,013,906 sh (-11.60%)
Sarah Ketterer 61,900 sh (-41.38%)
» More
Q3 2015

WX Guru Trades in Q3 2015

John Burbank 8,151 sh (New)
Mario Gabelli 61,300 sh (+13.10%)
Sarah Ketterer 65,400 sh (+5.65%)
Matthews Pacific Tiger Fund 2,243,158 sh (unchged)
Ron Baron 341,500 sh (unchged)
First Eagle Investment Sold Out
Columbia Wanger 578,000 sh (-42.99%)
» More
Q4 2015

WX Guru Trades in Q4 2015

Value Partners Sold Out
Mario Gabelli Sold Out
John Burbank Sold Out
Ron Baron Sold Out
Columbia Wanger Sold Out
Matthews Pacific Tiger Fund Sold Out
Sarah Ketterer Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with WX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Traded in other countries:3W11.Germany,
Headquarter Location:China

WuXi PharmaTech (Cayman) Inc was incorporated on March 16, 2007 and commenced operations and began offering pharmaceutical and biotechnology R&D outsourcing services in 2001. The Company is a pharmaceutical, biotechnology and medical device R&D services company, with operations in China and the United States. It provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers, which includes pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its customers in shortening the cycle and lowering the cost of pharmaceutical and medical device R&D by providing cost-effective and efficient outsourcing solutions. Its primary China-based facilities include 1,127,000 square feet of facilities in the China (Shanghai) Pilot Free Trade Zone used for synthetic chemistry, biology, medicinal chemistry, DMPK, formulation, analytical development, manufacturing process chemistry, research manufacturing, bioanalytical services, genomics, and biologics drug discovery and development; an R&D center in Tianjin engaged in synthetic chemistry and medicinal chemistry; a facility in Wuhan providing services in synthetic chemistry and medicinal chemistry; a small-scale cGMP clinical manufacturing facility and a large-scale cGMP commercial manufacturing plant in the Jinshan district of Shanghai; a large-scale non-GMP manufacturing plant in Changzhou; a preclinical toxicology facility in Suzhou; a laboratory for manufacturing research reagents in Suzhou; and a biologics manufacturing facility in Wuxi. It also offers services in biologics and medical device testing in three FDA-registered facilities in the United States. The Company has two segments: Laboratory services and Manufacturing services. Laboratory services are provided for pharmaceutical, biotechnology and medical device companies. China-based laboratory services for pharmaceutical and biotechnology companies include services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics. U.S.-based laboratory services include testing services for biologics, medical devices, and combination products. Manufacturing services include the development of manufacturing processes and the production of intermediates and active pharmaceutical ingredients, or APIs, for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologics. The Company offers testing and development services to ensure that a medical device is manufactured, packaged and sterilized in accordance with GMP guidelines. Its in vivo and in vitro toxicology testing includes biocompatibility or safe



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $778.48
EPS (TTM) $ 1.19
Short Percentage of Float0.35%
52-Week Range $32.50 - 46.14
Shares Outstanding (Mil)71.00 (ADR)

Analyst Estimate

Revenue (Mil $)
EPS ($) 14.40
EPS without NRI ($) 14.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat